We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Concerning the assessment of outcomes in the treatment of actinic cheilitis. Comment on: "Cheilitis Actinica: topical treatment with 3.75% imiquimod".
- Authors
Garbers, Luiz Eduardo Fabrício de Melo; Miola, Anna Carolina; Miot, Hélio Amante
- Abstract
Dear Editor, Actinic cheilitis (AC) is a subject of critical importance due to the high risk of malignization; however, systematic longitudinal large-sample controlled trials on AC treatment are scarce, leaving its treatment hierarchy undefined.1 The search for highly effective, affordable, and well-tolerated topical treatments for AC is relevant; therefore, we read with interest the manuscript from Dr. Kopera in which she reports that an elderly man with biopsy-proven AC was successfully treated with topical 3.75% imiquimod cream twice daily for 2 weeks.2 We commend the author for exploring a new therapeutic alternative and alerting dermatologists regarding outcomes of AC treatments. This characteristic substantiates the treatment of the whole lip, instead of the single AC lesion. Although AC can manifest as a single clinical lesion, the whole affected lip is genomically unstable, which is defined as field cancerization, and multicentric carcinogenesis can elicit new AC and malignancy.
- Subjects
IMIQUIMOD; CHEILITIS; TREATMENT effectiveness
- Publication
International Journal of Dermatology, 2022, Vol 61, Issue 7, pe241
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.16248